Citations

Clear

590 citation(s) found for "Ho, Ben".

Natural History, Complications and Re-Intervention Rates of Asymptomatic Residual Stone Fragments after Ureteroscopy: a Report from the EDGE Research Consortium
Brotherhood, Hilary, Sur, Roger L. , Wang, An Qi, Knudsen, Bodo E. , Yong, Courtney , Marien, Tracy , Miller, Nicole L. , Krambeck, Amy E. , Charchenko, Cameron, Humphreys, Mitchell R. , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | November 14, 2015 | Volume: 195 | Issue: 4 Part 1 | Pages: 982-986

10.1016/j.juro.2015.11.009 | PMID 26585680 Get It

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Hurley, Paula J. , Sundi, Debasish , Shinder, Brian , Hughes, Robert M. , Miller, Rebecca M., Benzon, Benjamin , Faraj, Sheila F., Netto, George J. , Vergara, Ismael A. , Erho, Nicholas , Karnes, R. Jeffrey , Yan, Guifang, Ewing, Charles M., Isaacs, Sarah D., Berman, David M. , Rider, Jennifer R. , Jordahl, Kristina M. , Mucci, Lorelei A. , Huang, Jessie , An, Steven S. , Isaacs, William B. , Marchionni, Luigi , Ross, Ashley E. , Schaeffer, Edward M. , Simons, Brian W. , Davicioni, Elai , Park, Ben Ho

Mayo Clinic

Clinical Cancer Research | October 7, 2015 | Volume: 22 | Issue: 2 | Pages: 448-458

10.1158/1078-0432.ccr-15-0256 | PMID 26446945 Get It

Abstract Purpose: Prostate cancers incite tremendous morbidity upon metastatic growth. We previously identified Asporin (ASPN) as a potential mediator of metastatic progression found within the tumor microenvironment. ASPN contains an aspartic acid (D)-repeat domain and germline polymorphisms in D-repeat-length have been associated with degenerative diseases. Associations of germline ASPN D polymorphisms with risk of prostate cancer progression to metastatic disease have not been assessed. Experimental Design: Germline ASPN D-repeat-length was retrospectively analyzed in 1,600 men who underwent radical prostatectomy for clinically localized prostate cancer and in 548 noncancer controls. Multivariable Cox proportional hazards models were used to test the associations of ASPN variations with risk of subsequent oncologic outcomes, including metastasis. Orthotopic xenografts were used to establish allele- and stroma-specific roles for ASPN D variants in metastatic prostate cancer. Results: Variation at the ASPN D locus was differentially associated with poorer oncologic outcomes. ASPN D14 [HR, 1.72; 95% confidence interval (CI), 1.05–2.81, P = 0.032] and heterozygosity for ASPN D13/14 (HR, 1.86; 95% CI, 1.03–3.35, P = 0.040) were significantly associated with metastatic recurrence, while homozygosity for the ASPN D13 variant was significantly associated with a reduced risk of metastatic recurrence (HR, 0.44; 95% CI, 0.21–0.94, P = 0.035) in multivariable analyses. Orthotopic xenografts established biologic roles for ASPN D14 and ASPN D13 variants in metastatic prostate cancer progression that were consistent with patient-based data. Conclusions: We observed associations between ASPN D variants and oncologic outcomes, including metastasis. Our data suggest that ASPN expressed in the tumor microenvironment is a heritable modulator of metastatic progression. Clin Cancer Res; 22(2); 448–58. ©2015 AACR.
Classification of current anticancer immunotherapies
Galluzzi, Lorenzo , Vacchelli, Erika , Pedro, José Manuel Bravo‐San , Buqué, Aitziber , Senovilla, Laura , Baracco, Elisa Elena, Bloy, Norma , Castoldi, Francesca , Abastado, Jean-Pierre, Agostinis, Patrizia , Apte, Ron N., Aranda, Fernando , Ayyoub, Maha , Beckhove, Philipp , Blay, Jean‐Yves , Bracci, Laura , Caignard, Anne , Cavallo, Federica , Celis, Estaban, Clayton, Aled , Coussens, Lisa M. , Dhodapkar, Madhav V. , Eggermont, Alexander , Fearon, Douglas T. , Fučíková, Jitka , Galon, Jérôme , Garg, Abhishek D. , Ghiringhelli, François , Gilboa, Eli , Gnjatic, Sacha , Hoos, Axel , Jäger, Dirk, Kaliński, Paweł , Kärre, Klas , Kepp, Oliver , Kiessling, Rolf , Klein, Eva, Knuth, Alexander, Lewis, Claire E. , Lugli, Enrico , Mach, J P, Mattei, Fabrizio , Mavilio, Domenico , Melero, Ignacio , Melief, Cornelis J.M., Moretta, Lorenzo , Odunsi, Adekunke, Palucka, A. Karolina, Porgador, Angel , Prendergast, George C. , Restifo, Nicholas P. , Rizvi, Naiyer A. , Schreiber, Hans , Seliger, Barbara , Shiku, Hiroshi , Špíšek, Radek , Srivastava, Pramod K. , Vile, Richard G. , Wagner, Hermann, Weber, Jeffrey S. , Zitvogel, Laurence , Zou, Weiping , Abastado, Jean‐Pierre, Castelli, Chiara , Cerundolo, Vincenzo , Colombo, Mario P. , Fridman, Wolf H. , Gabrilovich, Dmitry I. , Giaccone, Giuseppe , Hosmalin, Anne , Kirkwood, John M. , Liblau, Roland , Lotze, Michael T. , Mittendorf, EA , Okada, Hideho , Peter, Marcus E. , Pienta, Kenneth J , Rabinovich, Gabriel A , Sautès‐Fridman, Catherine , Silva‐Santos, Bruno , Smyth, Mark J. , Speiser, Daniel E. , Talmadge, James E. , Tartour, Éric , Burg, Sjoerd H. van der , Eynde, Benoı̂t J. Van den , Whiteside, Theresa L , Wolchok, Jedd D. , Kroemer, Guido , Gnjatic, Sacha , Blay, Jean-Yves , Galon, Jerome , Weber, Jeffrey

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 5 | Issue: 24 | Pages: 12472-12508

10.18632/oncotarget.2998 | PMID 25537519 Get It

Abstract LB-028: Cell density sensing alters TGF-beta signaling in a cell type-specific manner, independent from Hippo pathway activation
Nallet-Staub, Flore, Yin, Xueqian , Gilbert, Cristèle , Marsaud, Véronique, Mimoun, Saber Ben, Leof, Edward B. , Javelaud, Delphine , Mauviel, Alain

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-028-LB-028

10.1158/1538-7445.am2015-lb-028 Get It

Abstract Cell-cell contacts inhibit cell growth and proliferation in part by activating the Hippo pathway that drives the phosphorylation and nuclear exclusion of the transcriptional coactivators YAP and TAZ. Cell density and Hippo signaling have also been reported to block TGF-β responses, based on the ability of phospho-YAP/TAZ to sequester TGF-β-activated SMAD complexes in the cytoplasm. Herein, we provide evidence that epithelial cell polarization interferes with TGF-β signaling well upstream and independent of cytoplasmic YAP/TAZ. Rather, polarized basolateral presentation of TGF-β receptors I and II deprives apically delivered TGF-β of access to its receptors. Basolateral ligand delivery nonetheless remains entirely effective to induce TGF-β responses. These data demonstrate that cell type-specific inhibition of TGF-β signaling by cell density is restricted to polarized epithelial cells and reflects the polarized distribution of TGF-β receptors, which thus impacts SMAD activation irrespective of Hippo pathway activation. Citation Format: Flore Nallet-Staub, Xueqian Yin, Cristèle Gilbert, Véronique Marsaud, Saber Ben Mimoun, Delphine Javelaud, Edward B. Leof, Alain Mauviel. Cell density sensing alters TGF-beta signaling in a cell type-specific manner, independent from Hippo pathway activation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-028. doi:10.1158/1538-7445.AM2015-LB-028
Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora , Geyer, Susan, Sanford, Ben L. , Bennett, Elizabeth , Chanan‐Khan, Asher , Bloomfield, Clara D. , Larson, Richard A. , Chanan-Khan, Asher A., Orlowski, Robert Z. , Watson, Peter J. , Larson, Richard A

Mayo Clinic

British Journal of Haematology | July 22, 2015 | Volume: 171 | Issue: 3 | Pages: 373-377

10.1111/bjh.13592 | PMID 26202857 Get It

SummaryLong‐term outcomes and updated clinical efficacy and safety data were evaluated for newly‐diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near‐complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment‐related ≥Grade 3 non‐haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation
Rojnueangnit, Kitiwan , Xie, Jing , Gomes, Alicia , Sharp, Angela, Callens, Tom, Chen, Yunjia , Liu, Ying , Abbott, Mary‐Alice , Atkin, Joan, Babovic‐Vuksanovic, Dusica , Barnett, Christopher , Crenshaw, Melissa , Bartholomew, Dennis W., Basel, Lina, Bellus, Gary A. , Ben‐Shachar, Shay , Bialer, Martin G., Bick, David , Blumberg, Bruce , Cortés, Fanny, David, Karen L. , Destrèe, Anne , Rodríguez, Anna Duat , Earl, Dawn , Eswara, Marthanda, Ezquieta, Begoña, Frayling, Ian M. , Frydman, Moshe , Gardner, Kathy, Gripp, Karen W. , Hernández‐Chico, Concepción, Heyrman, Kurt, Ibrahim, Jennifer, Janssens, Sandra , Keena, Beth, Llano‐Rivas, Isabel , Leppig, Kathy, McDonald, Marie , Misra, Vinod K. , Mulbury, Jennifer, Narayanan, Vinodh , Orenstein, Naama, Galvin‐Parton, Patricia , Pedro, Hélio , Pivnick, Enikö K., Powell, Cynthia M. , Randolph, Linda M., Raskin, Salmo , Rubin, Karol, Seashore, Margretta R., Schaaf, Christian P. , Schultz, Meredith, Schorry, Elizabeth K. , Schnur, Rhonda E. , Siqveland, Elizabeth, Tkachuk, Amanda , Tonsgard, James H. , Upadhyaya, Meena , Verma, Ishwar C. , Wallace, Stephanie E , Williams, Charles A. , Zackai, Elaine H. , Zonana, Jonathan, Lázaro, Conxi , Claes, Kathleen , Korf, Bruce R. , Messiaen, Ludwine , Babovic-Vuksanovic, Dusica, Cochran, J. Nicholas , Escobar, Luis Fernando , Hernández-Chico, Concepción, Rosell, Jordi , Scheuerle, Angela E. , Martín, Yolanda , Legius, Eric , Claes, Kathleen B M , Lazaro, Conxi

Mayo Clinic

Human Mutation | July 14, 2015 | Volume: 36 | Issue: 11 | Pages: 1052-1063

10.1002/humu.22832 | PMID 26178382 Get It

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Loh, Mignon L. , Brown, Patrick A. , Magoon, Daniel, Chen, Xuejun , Ahern, Charlotte H., Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Tasian, Sarah K. , Rabin, Karen R. , Loh, Mignon L

Mayo Clinic

Pediatric Blood & Cancer | May 13, 2015 | Volume: 62 | Issue: 10 | Pages: 1717-1724

10.1002/pbc.25575 | PMID 25976292 Get It

Abstract LB-196: Preventing breast cancer metastases with an anti-angiogenic and anticancer RGD-bearing nanomedicine
Eldar‐Boock, Anat , Lupu, Ruth , Vicent, Marı́a J. , Ben‐Shushan, Dikla , Sanchis, Joaquı́n , Satchi‐Fainaro, Ronit

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: LB-196-LB-196

10.1158/1538-7445.am2014-lb-196 Get It

Abstract Overcoming drug resistance, emerging either on recurring cancer or metastasis, is a major challenge of cancer treatments. The combination of anti-angiogenic agents with chemotherapeutic ones offers a promising therapeutic approach. Such combination can be achieved exploiting the multivalency of polymer therapeutics. We have recently showed that polymer conjugation of paclitaxel (PTX), a potent cytotoxic and anti-angiogenic drug, improved its pharmacokinetic profile. We hypothesized that actively targeting PTX to αvβ3-integrin, presents an attractive therapeutic strategy for breast cancer. Interestingly, overexpression of αvβ3-integrin, occurring on tumor endothelial and some epithelial cells during tumor growth, invasion, and metastasis, was found to correlate with PTX-resistance of breast cancer cells. We designed and synthesized a novel polyglutamic acid (PGA)-PTX-E-[c(RGDfK)2] nano-sized conjugate. Polymer conjugation converted PTX to a water-soluble macromolecule, which passively targeted the tumor tissue exploiting the enhanced permeability and retention (EPR) effect. The E-[c(RGDfK)2] was utilized as an additional active targeting moiety to αvβ3 integrin. PGA is enzymatically-degradable by cathepsin B, leading to PTX release. PGA-PTX-E-[c(RGDfK)2] displayed a potent anti-angiogenic activity, determined by several well-established in vitro assays. Preferential tumor accumulation of the RGD-bearing conjugate in orthotopic mammary tumors inoculated in mice, lead to enhanced antitumor efficacy and a marked decrease in toxicity compared with free PTX. We found that metastasis establishment was dependent on αvβ3-integrin expression as determined in vitro and ex vivo. PGA-PTX-E-[c(RGDfK)2] conjugate inhibited metastatic growth in an experimental breast cancer metastases model in mice. Taken together, inclusion of an active targeting moiety to integrin expressing-cells has the potential to decrease breast cancer metastases establishment by displaying an anti-angiogenic and anticancer activity. Citation Format: Anat Eldar-Boock, Dikla Ben-Shushan, Joaquin Sanchis, Ruth Lupu, Maria J. Vicent, Ronit Satchi-Fainaro. Preventing breast cancer metastases with an anti-angiogenic and anticancer RGD-bearing nanomedicine. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-196. doi:10.1158/1538-7445.AM2014-LB-196
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults
Pérez-Andreu, Virginia, Zhang, Hui , Harvey, Richard C. , Payne-Turner, Debbie , Cheng, I-Ming, Carroll, William L. , Heerema, Nyla A. , Carroll, Andrew J. , Raetz, Elizabeth A. , Marcucci, Guido , Bloomfield, Clara D. , Mrózek, Krzysztof , Kohlschmidt, Jessica, Konopleva, Marina , Paietta, Elisabeth , Rowe, Jacob M. , Luger, Selina M. , Tallman, Martin S. , Dean, Michael , Torgerson, Dara G., Wang, Yanli , Relling, Mary V. , Evans, William E. , Gerhard, Daniela S., Loh, Mignon L. , Mullighan, Charles G. , Roberts, Kathryn G. , Xu, Heng Yi , Smith, Colton J. , Yang, Wenjian , Devidas, Meenakshi , Gastier‐Foster, Julie M. , Stock, Wendy , Kornblau, Steven M. , Burchard, Esteban G. , Yue, Feng , Pui, Ching-Hon , Jeha, Sima , Willman, Cheryl L. , Hunger, Stephen P. , Yang, Jun J.J. , Mullighan, Charles G , Harvey, Richard , Loh, Mignon L , Dean, Michael

Mayo Clinic

Blood | December 3, 2014 | Volume: 125 | Issue: 4 | Pages: 680-686

10.1182/blood-2014-09-595744 | PMID 25468567 Get It

Key PointsIn this first ALL GWAS in AYAs, we determined that inherited GATA3 variants strongly influence ALL susceptibility in this age group. These findings revealed similarities and differences in the genetic basis of ALL susceptibility between young children and AYAs.
Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Bartholdy, Boris , Zhou, Li , Todorova, Tihomira I. , Stanley, Robert , Parekh, Samir , Paietta, Elisabeth , Cripe, Larry D., Fernández, Hugo F. , Greenberg, Peter L. , Rowe, Jacob M. , Tallman, Martin S. , Mitsiades, Constantine S. , Steidl, Ulrich , Barreyro, Laura , Mitchell, Kelly , Will, Britta , Ben‐Neriah, Susana , Montagna, Cristina , Pellagatti, Andrea , Boultwood, Jacqueline , Ketterling, Rhett P. , Steidl, Christian , Verma, Amit , Parekh, Samir

Mayo Clinic

Molecular Cancer Therapeutics | August 14, 2014 | Volume: 12 | Issue: 11_Supplement | Pages: C225-C225

10.1158/1535-7163.targ-13-c225 Get It

Abstract Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS and cure rates remain below 20%. AML/MDS arise following the accumulation of stepwise genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPC). Utilizing a novel strategy of parallel transcriptional analysis of sorted HSPC populations in distinct subtypes of AML, we compared the gene expression in AML HSPC with identical compartments from age-matched healthy controls and identified Interleukin 1 receptor accessory protein (IL1RAP) as one of the most significantly upregulated genes in HSPC in all examined subtypes of AML. Fluorescence in situ hybridization of sorted IL1RAP+ and IL1RAP- cells from patients with monosomy 7 AML (-7) indicated that the aberrant clone was restricted to IL1RAP+ cells, demonstrating that IL1RAP overexpression is a distinguishing feature of the -7 clone. Multivariate analysis of a large cohort of patients with normal karyotype AML showed that patients with high IL1RAP levels had inferior overall survival than patients with lower IL1RAP levels, suggesting an independent prognostic value for this molecule in AML. IL1RAP expression levels in MDS were found elevated on stem cells of patients with high risk disease, proposing a role of IL1RAP in higher risk MDS and progression to AML. Downregulation of IL1RAP expression by lentivirally expressed shRNAs decreased clonogenicity in cell lines and AML/MDS primary patient samples, induced apoptosis of AML cells, and reduced proliferation of AML cells and infiltration of hematopoietic organs in vivo. IL1RAP is a transmembrane protein required for signaling through several receptors of the IL1 family. Downregulation of IL1RAP expression in AML cells led to phosphorylation changes in several kinases and their substrates suggesting participation of IL1RAP in multiple signaling pathways and highlighting its potential as therapeutic target. We investigated whether inhibition of IL1RAP with pharmacological compounds is feasible and effective. Antibody-mediated inhibition of IL1RAP led to inhibition of AML cell growth in vitro. In addition, we designed peptides to interfere with IL1RAP-receptor interactions which lead to inhibition of AML cell growth. Both types of agents are being further tested and optimized. In summary, our study reveals IL1RAP as aberrantly expressed on HSPC of AML and high-risk MDS patients. Inhibition of IL1RAP is feasible and functionally effective, and thus has the potential to lead to novel therapies specifically directed at such stem cells. Beyond IL1RAP, our study provides a map of dysregulated transcripts in HSPC from patients with AML, which may offer further opportunities for therapeutic intervention. The strategy of comparative analysis of sorted stem and progenitor cells in cancer versus healthy controls may be applicable to other type of cancers with a suspected stem cell origin, and instrumental for the identification of targets for stem cell-directed therapy. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C225. Citation Format: Laura Barreyro, Kelly Mitchell, Britta Will, Boris Bartholdy, Li Zhou, Tihomira Todorova, Robert Stanley, Susana Ben-Neriah, Cristina Montagna, Samir Parekh, Andrea Pellagatti, Jacqueline Boultwood, Elisabeth Paietta, Rhett Ketterling, Larry Cripe, Hugo Fernandez, Peter Greenberg, Jacob Rowe, Martin Tallman, Christian Steidl, Constantine Mitsiades, Amit Verma, Ulrich Steidl. IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C225.